Relay Therapeutics 

Yahoo Finance • 2 days ago

Erasca, Inc. (ERAS): A Bull Case Theory

We came across a bullish thesis on Erasca, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ERAS. Erasca, Inc.'s share was trading at $12.39 as of February 19th.Cidara (CDTX) Climbs 105% on $... Full story

Yahoo Finance • 10 days ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story

Yahoo Finance • 2 months ago

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics GAAP EPS of -$0.43 misses by $0.02

* Relay Therapeutics press release [https://seekingalpha.com/pr/20297824-relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates] (RLAY [https://seekingalpha.com/symbol/RLAY]): Q3 GAAP EPS of -$0.43 misses by... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 6 months ago

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week

Key Points An analyst initiated coverage of the biotech. Not only does he consider it a buy, he's also designated it as one of his firm's top picks.10 stocks we like better than Relay Therapeutics › Precision medicine specialist Relay Th... Full story

Yahoo Finance • 6 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story

Yahoo Finance • 7 months ago

Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company specializing in precision medicine and AI-driven drug discovery, stands at a critical juncture in its development. With its lead candidate RLY-2608 progressing through clinica... Full story

Yahoo Finance • 7 months ago

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase3ReDiscover-2trial in Q2 Approximately $657... Full story

Yahoo Finance • 7 months ago

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 9 months ago

Relay Therapeutics' SWOT analysis: AI-driven drug discovery stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company with a market capitalization of $552 million focused on AI-driven drug discovery, stands at a critical juncture in its development of RLY-2608, a mutant-selective PI3Ka inhibi... Full story

Yahoo Finance • 9 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 9 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc. (RLAY)'s share was trading at $3.23 as of 4th June. A re... Full story

Yahoo Finance • 9 months ago

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in... Full story

Yahoo Finance • 9 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tech... Full story

Yahoo Finance • 10 months ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Cash runway extended into 2029 Initiation of Phase3ReDiscover-2trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past... Full story

Yahoo Finance • 11 months ago

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other biotech penny stocks. Peter... Full story

Yahoo Finance • 11 months ago

Barbara Weber, M.D., Elected to ITM Supervisory Board

Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. Th... Full story

Yahoo Finance • 11 months ago

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

We recently published a list of Top 9 AI Ratings and News Updates on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other top AI ratings and news updates on W... Full story

Yahoo Finance • last year

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story